Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad's Droplet Digital PCR ...
Philadelphia, March 27, 2025 – Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), ...
Resistance to imatinib during the treatment of chronic myeloid leukaemia (CML) is frequently associated with point mutations in the ABL gene encoding the ATP binding region likely to cause disease ...
Early molecular response in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with dasatinib (DAS) or imatinib (IM) from DASISION. Survival outcomes of sustained MR4.5 in ...
Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for ...
Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for ...
Several therapeutic options exist for patients who relapse following allogeneic SCT; immunosuppressant withdrawal, donor leukocyte infusion (DLI), interferon-α, and second transplantation. Most of ...
Bio-Rad Laboratories has received FDA clearance for two digital PCR products designed to monitor patients’ molecular responses to tyrosine kinase inhibitor treatments in chronic myeloid leukemia. The ...
2022—Cellecta, Inc. today announced the launch of the DriverMap™ Adaptive Immune Receptor (AIR) TCR and BCR kits, a family of multiplex-PCR, NGS-based assays that enable profiling of up to all seven T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback